Deflazacort Oral Suspension (DEFLAZACORT)
Deflazacort Oral Suspension (DEFLAZACORT) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Deflazacort Oral Suspension; Generic name: DEFLAZACORT; Drug class: Corticosteroid [EPC].
| Brand name | Deflazacort Oral Suspension |
|---|---|
| Generic name | DEFLAZACORT |
| Drug class | Corticosteroid [EPC] |
| Manufacturer | Zydus Pharmaceuticals (USA) Inc. |
| Used for | 1 INDICATIONS AND USAGE Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza™ (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information . Deflazacort oral suspension is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally ( 2.2 ) Discontinue gradually when administered for more than a few days ( 2.3 ) 2.1 Assessments Prior to First Dose of Deflazacort Oral Suspension Administer all immunizations according to immunization guidelines prior to starting deflazacort oral suspension. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting deflazacort oral suspension [see Warnings |
| Active ingredient(s) | DEFLAZACORT |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14569f71-573e-49fd-b80e-b3b52531b1c8 |